HUP9801697A2 - Új protein és eljárás előállítására - Google Patents

Új protein és eljárás előállítására

Info

Publication number
HUP9801697A2
HUP9801697A2 HU9801697A HUP9801697A HUP9801697A2 HU P9801697 A2 HUP9801697 A2 HU P9801697A2 HU 9801697 A HU9801697 A HU 9801697A HU P9801697 A HUP9801697 A HU P9801697A HU P9801697 A2 HUP9801697 A2 HU P9801697A2
Authority
HU
Hungary
Prior art keywords
subject
protein according
treatment
protein
thermodimer
Prior art date
Application number
HU9801697A
Other languages
English (en)
Inventor
Koichi Enomoto
Mieko Katsuura
Shinji Kawai
Michio Kimura
Fusao Makishima
Tomoaki Matsumoto
Hideo Miki
Yusuke Satoh
Hiroyuki Takamatsu
Original Assignee
Hoechst Marion Roussel Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Marion Roussel Ltd. filed Critical Hoechst Marion Roussel Ltd.
Publication of HUP9801697A2 publication Critical patent/HUP9801697A2/hu
Publication of HUP9801697A3 publication Critical patent/HUP9801697A3/hu
Publication of HU225424B1 publication Critical patent/HU225424B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

A találmány tárgyát egy MP52-prőteinből származó, a szekvencialistábanbeműtatőtt 1. azőnősítószámú szekvenciát tartalmazó prőtein, valamintannak hőmődimere képezi. A találmány tárgyát képezi tővábbá egy pőrc-és csőntbetegségek kezelésére alkalmas gyógyászati készítmény, amelyaktív hatóanyagként a találmány szerinti dimer prőteint tartalmazza. Szintén a találmány tárgyát képezi egy eljárás a találmány szerintiprőtein nagy mennyiségben és nagy tisztaságban történő előállítására,melynek sőrán a találmány szerinti prőtein expresszálására képes DNS-szekvenciát tartalmazó plazmiddal transzfőrmált E. cőli sejtekettenyésztenek. A találmány tárgyát képezik tővábbá eljárásők pőrc- éscsőntbeteségek kezelésére. A találmány szerinti hőmődimer prőtein csőntalak-fejlődési aktivitástfejt ki, ezért alkalmas pőrc- és csőntbetegségek kezelésrée. ŕ
HU9801697A 1995-04-19 1996-04-19 Modified mp52-protein and process for producing thereof HU225424B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP9366495 1995-04-19
JP32240395 1995-11-17
PCT/JP1996/001062 WO1996033215A1 (fr) 1995-04-19 1996-04-19 Proteine nouvelle et son procede de fabrication

Publications (3)

Publication Number Publication Date
HUP9801697A2 true HUP9801697A2 (hu) 1998-10-28
HUP9801697A3 HUP9801697A3 (en) 2000-06-28
HU225424B1 HU225424B1 (en) 2006-11-28

Family

ID=26434967

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9801697A HU225424B1 (en) 1995-04-19 1996-04-19 Modified mp52-protein and process for producing thereof

Country Status (18)

Country Link
US (3) US7235527B2 (hu)
EP (1) EP0955313B1 (hu)
AT (1) ATE325131T1 (hu)
AU (1) AU704515C (hu)
BR (1) BR9608019A (hu)
CA (1) CA2216741C (hu)
DE (2) DE69636728T4 (hu)
DK (1) DK0955313T3 (hu)
EA (1) EA000582B1 (hu)
ES (1) ES2258774T3 (hu)
HU (1) HU225424B1 (hu)
NO (1) NO321153B1 (hu)
NZ (1) NZ305472A (hu)
OA (1) OA10528A (hu)
PL (1) PL186518B1 (hu)
PT (1) PT955313E (hu)
UA (1) UA46767C2 (hu)
WO (1) WO1996033215A1 (hu)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6586388B2 (en) 1988-04-08 2003-07-01 Stryker Corporation Method of using recombinant osteogenic protein to repair bone or cartilage defects
US20070166353A1 (en) * 1988-04-08 2007-07-19 Stryker Corporation Osteogenic proteins
US20080233170A1 (en) * 1992-02-21 2008-09-25 Stryker Corporation Osteogenic Proteins
ZA9711580B (en) * 1996-12-25 1999-09-23 Hoechst Marion Roussel Ltd Process for the production of purified dimeric bone morphogenetic factors.
HU226554B1 (en) * 1997-01-30 2009-03-30 Bioph Biotech Entw Pharm Gmbh Freeze-dried composition of bone morphogenetic protein human mp52
EP1350525A3 (en) † 1997-02-07 2003-12-10 Stryker Corporation Matrix-free osteogenic devices, implants and methods thereof
US6727224B1 (en) 1999-02-01 2004-04-27 Genetics Institute, Llc. Methods and compositions for healing and repair of articular cartilage
KR100775958B1 (ko) 2005-03-30 2007-11-13 김정문 조직재생 기능을 가지는 비활성 폴리펩티드 및 그 제조방법
US20070105762A1 (en) * 2005-03-30 2007-05-10 Jung Kim Non-activated polypeptides having a function of tissue regeneration and method for preparing the same
US20060286144A1 (en) * 2005-06-17 2006-12-21 Chunlin Yang Reinforced collagen scaffold
ATE553123T1 (de) 2005-11-18 2012-04-15 Bioph Biotech Entw Pharm Gmbh Wachstumsfaktormutanten mit hoher aktivität
EP1880731A1 (en) * 2006-07-18 2008-01-23 BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA mbH Human growth and differentiation factor GDF-5
AU2007234612B2 (en) * 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
SI2121142T1 (sl) * 2007-01-25 2012-12-31 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh Uporaba GDF-5 za izboljšanje ali vzdrževanje videza kože
US7678764B2 (en) 2007-06-29 2010-03-16 Johnson & Johnson Regenerative Therapeutics, Llc Protein formulations for use at elevated temperatures
EP2019117A1 (en) * 2007-07-27 2009-01-28 BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA mbH Optimized purification process of recombinant growth factor protein
EP2187932B1 (en) 2007-08-07 2015-01-28 DePuy Synthes Products, LLC Protein formulations comprising gdf-5 in aqueous acidic solution
JP2009106163A (ja) * 2007-10-26 2009-05-21 Kyushu Univ 核酸配列、ベクター、形質転換体、製造方法、及び、核酸配列プライマー
WO2009129101A1 (en) 2008-04-14 2009-10-22 Advanced Technologies And Regenerative Medicine, Llc Liquid buffered gdf-5 formulations
US11260110B2 (en) 2009-11-18 2022-03-01 Ptlnv, Llc, Series Four (4) Nanoparticles for the therapeutic treatment of radiation-induced skin ulcers
US9226898B1 (en) * 2009-11-18 2016-01-05 Richard C. K. Yen Submicron particles for the treatment of radiation damage in patients
CA2806143A1 (en) 2010-07-30 2012-02-02 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mb H Drug delivery devices and growth factor formulations for accelerated wound healing
US8551525B2 (en) 2010-12-23 2013-10-08 Biostructures, Llc Bone graft materials and methods
US8524662B2 (en) 2010-12-28 2013-09-03 Depuy Mitek, Llc Compositions and methods for treating joints
US8455436B2 (en) 2010-12-28 2013-06-04 Depuy Mitek, Llc Compositions and methods for treating joints
US8398611B2 (en) 2010-12-28 2013-03-19 Depuy Mitek, Inc. Compositions and methods for treating joints
EP2537538A1 (en) 2011-06-22 2012-12-26 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka mbH Bioresorbable Wound Dressing
US8623839B2 (en) 2011-06-30 2014-01-07 Depuy Mitek, Llc Compositions and methods for stabilized polysaccharide formulations
EP2602264A1 (en) 2011-12-05 2013-06-12 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka mbH GDF-5 mutant for inducing cartilage formation
US9682099B2 (en) 2015-01-20 2017-06-20 DePuy Synthes Products, Inc. Compositions and methods for treating joints
JP2023507007A (ja) 2019-12-18 2023-02-20 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 疼痛及び軟骨破壊を治療するためのｇｄｆ－５変異体の使用
KR20240064367A (ko) * 2022-11-04 2024-05-13 주식회사 대웅제약 TGF-β3 단백질의 정제방법

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4725234A (en) * 1985-08-15 1988-02-16 Ethridge Edwin C Alveolar bone grafting process with controlled surface active ceramics
US5079352A (en) * 1986-08-22 1992-01-07 Cetus Corporation Purified thermostable enzyme
US5354557A (en) * 1988-04-08 1994-10-11 Stryker Corporation Osteogenic devices
GB8927546D0 (en) * 1989-12-06 1990-02-07 Ciba Geigy Process for the production of biologically active tgf-beta
US5143829A (en) * 1990-03-29 1992-09-01 California Biotechnology Inc. High level expression of basic fibroblast growth factor having a homogeneous n-terminus
US5118667A (en) * 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
US5171579A (en) * 1991-10-11 1992-12-15 Genetics Institute, Inc. Formulations of blood clot-polymer matrix for delivery of osteogenic proteins
WO1993009229A1 (en) 1991-11-04 1993-05-13 Genetics Institute, Inc. Recombinant bone morphogenetic protein heterodimers, compositions and methods of use
NZ249113A (en) 1992-02-12 1996-07-26 Bioph Biotech Entw Pharm Gmbh Recombinant dna encoding tgf-b, its production and pharmaceutical compositions thereof
CA2153654A1 (en) 1993-01-12 1994-07-21 Se-Jin Lee Growth differentiation factor-5
IL110589A0 (en) 1993-08-10 1994-11-11 Bioph Biotech Entw Pharm Gmbh Growth/differentiation factor of the TGF- beta family
US6248554B1 (en) 1993-11-24 2001-06-19 The Procter & Gamble Company DNA sequence coding for a BMP receptor
US5399677A (en) 1993-12-07 1995-03-21 Genetics Institute, Inc. Mutants of bone morphogenetic proteins
ATE319823T1 (de) * 1993-12-07 2006-03-15 Inst Genetics Llc Bmp-12, bmp-13 und diese enthaltende sehne- induzierende zusammensetzungen
US5707962A (en) * 1994-09-28 1998-01-13 Gensci Regeneration Sciences Inc. Compositions with enhanced osteogenic potential, method for making the same and therapeutic uses thereof

Also Published As

Publication number Publication date
ATE325131T1 (de) 2006-06-15
DK0955313T3 (da) 2006-08-21
DE69636728T4 (de) 2007-06-28
EP0955313A4 (en) 2001-11-07
US20020102633A1 (en) 2002-08-01
AU704515C (en) 2002-03-28
HU225424B1 (en) 2006-11-28
NO321153B1 (no) 2006-03-27
WO1996033215A1 (fr) 1996-10-24
US20090325864A1 (en) 2009-12-31
PL322945A1 (en) 1998-03-02
EA199700329A1 (ru) 1998-04-30
US7235527B2 (en) 2007-06-26
CA2216741A1 (en) 1996-10-24
NZ305472A (en) 1999-09-29
EP0955313B1 (en) 2006-05-03
OA10528A (en) 2002-04-26
CA2216741C (en) 2008-01-15
HUP9801697A3 (en) 2000-06-28
DE69636728D1 (de) 2007-01-04
BR9608019A (pt) 1999-11-30
ES2258774T3 (es) 2006-09-01
NO974812D0 (no) 1997-10-17
US7816103B2 (en) 2010-10-19
AU704515B2 (en) 1999-04-22
NO974812L (no) 1997-12-19
UA46767C2 (uk) 2002-06-17
PL186518B1 (pl) 2004-01-30
DE69636728T2 (de) 2007-02-22
EA000582B1 (ru) 1999-12-29
AU5347096A (en) 1996-11-07
MX9708011A (es) 1998-03-31
PT955313E (pt) 2006-07-31
US20030181378A1 (en) 2003-09-25
EP0955313A1 (en) 1999-11-10
US7268114B2 (en) 2007-09-11

Similar Documents

Publication Publication Date Title
HUP9801697A2 (hu) Új protein és eljárás előállítására
IL207348A0 (en) Circular dna molecules, processes for their preparation, pharmaceutical compositions comprising them, and use thereof in the manufacture of medicinal products for producing recombinant proteins in vivo
AU4703796A (en) Stable lipid-comprising drug delivery complexes and methods for their production
AU2790292A (en) Viral recombinant vectors for expression in muscle cells
HUP9901314A2 (hu) Készítmények és eljárás biológiai anyagok stabilizálására szárítóeljárással befagyasztás nélkül
NO306614B1 (no) Derivater i vitamin D-serien modifisert ved 20-stilling, mellomprodukter anvendt ved fremstilling av disse, farmasöytiske preparater inneholdende derivatene og deres anvendelse ved fremstilling av legemidler
DE3855523D1 (de) Proteine mit Faktor-VIII-Aktivität, Verfahren zu deren Herstellung unter Verwendung von genetisch modifizierten Zellen und diese enthaltende pharmazeutische Zusammensetzungen
ATE315050T2 (de) Verfahren zur herstellung von mehrfach vernetzten hyaluronsäurederivaten
FI103278B1 (fi) Menetelmä biologisesti aktiivisen TGF- :n kaltaisen proteiinin tuottamiseksi
HUT37815A (en) Process for production of human polipeptids having gamma-interferon activity
CA2030108A1 (en) Process for the preparation of genetic vectors for the expression of nerve growth factor in eukaryotic cells
Mullenbach et al. Chemical synthesis and expression in yeast of a gene encoding connective tissue activating peptide-III. A novel approach for the facile assembly of a gene encoding a human platelet-derived mitogen.
DE69012377D1 (de) Polypeptid und dessen Herstellung.
PT775159E (pt) Novo processo de producao de proteina dimerica biologicamente activa
HUT58037A (en) Process for producing n-2,3-butadienyl tri- and tetraaminoalkane derivatives
HUT46224A (en) Process for producing pharmaceutical compositions containing prostaglandin e1-derivatives
SE0102204D0 (sv) New method
DE69027466D1 (de) Achromobacter-Protease-I-Gen sowie Genprodukt
WO1989009824A3 (en) Gene synthesis
RU94000724A (ru) Новые производные 17,20-эпоксидов прегнана, способ их получения, получение кортизонных производных и промежуточные соединения
FR2428049A1 (fr) Nouveaux antibiotiques obtenus notamment a partir d'une souche de micromonosporaceae, leur preparation et leur application en therapeutique
CA2102043A1 (en) Mutant aox2 promoter, vector carrying same, transformant, and production of heterologous protein
HUP9800520A2 (hu) Génexpresszió emlős sejtekben
DE69311295D1 (de) 16-(quaternär-Ammoniak)-substituierte Androstan-Derivate, pharmazeutische Präparate davon und ein Verfahren zu ihrer Herstellung
HUP9802915A2 (hu) Új sztafilokinázszármazékok

Legal Events

Date Code Title Description
MM4A Lapse of definitive patent protection due to non-payment of fees